CDK4 and breast cancer: Importantly, because DUBs are amenable to pharmacological inhibition by small molecule inhibitors,46 targeting USP51 to reduce ZEB1 stability in conjunction with CDK4/6 inhibitors represents a new therapeutic strategy that could deplete ZEB1 protein and overcome metastasis and therapy resistance in breast cancer.